Cited by 382Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.

Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

Mollenhauer, Brit, Cullen, Valerie, Kahn, Ilana, Krastins, Bryan, Outeiro, Tiago F., Pepivani, Imelda, Ng, Juliana, Schulz-Schaeffer, Walter, Kretzschmar, Hans A., McLean, Pamela J., Trenkwalder, Claudia, Sarracino, David A., VonSattel, Jean-Paul, Locascio, Joseph J., El-Agnaf, Omar M.A., Schlossmacher, Michael G.·2008·Experimental Neurology

DOI 10.1016/j.expneurol.2008.06.004

Open this paper in CoChat — free account

Abstract

Because accumulation of alpha-synuclein (alphaS) in the brain is a hallmark of Parkinson disease (PD) and related disorders, we examined its occurrence in human cerebrospinal fluid (CSF). Following affinity enrichment and trypsin digestion of CSF collected from a neurologically healthy donor, we identified several alphaS-derived peptides by mass spectrometry. The concentration of alphaS amounted to <0.001% of the CSF proteome. We then built, validated and optimized a sandwich-type, enzyme-linked immunoadsorbent assay (ELISA) to measure total alphaS levels in unconcentrated CSF. In a cross-sectional study of 100 living donors, we examined cell-free CSF samples from subjects clinically diagnosed with advanced PD, dementia with Lewy bodies (DLB), Alzheimer disease (AD), and a group of non-neurodegenerative disease controls (NCO). In these four groups the CSF alphaS concentrations ranged from 0.8 to 16.2 pg/microl. Mean CSF alphaS values were lower in donors with a primary synucleinopathy (PD, DLB: n=57) than in the other two groups (AD, NCO: n=35; p=0.025). By contrast, living Creutzfeldt-Jakob disease patients showed markedly elevated CSF alphaS levels (n=8; mean, 300 pg/microl; p<0.001). Our results unequivocally confirm the presence of alphaS in adult human CSF. In a first feasibility study employing a novel ELISA, we found relatively low CSF alphaS concentrations in subjects with parkinsonism linked to synucleinopathy, PD and DLB. In definite prion disease cases, we recorded a marked rise in total CSF alphaS resulting from rapid cell death. Our results will likely aid future biomarker explorations in neurodegenerative conditions and facilitate target validation studies.

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2008.06.004

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Retracted: Dopamine receptor immunohistochemistry in the rat choroid plexus
Mignini, F., Bronzetti, E., Felici, L., Rícci, A., Sabbatini, M., Tayebati, S. K., & Amenta, F. (2000) · Journal of Autonomic Pharmacology · doi:10.1046/j.1365-2680.2000.00198.x · Cited by 25
Retracted
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
α-Synuclein in Lewy bodies
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Levodopa and the Progression of Parkinson's Disease
The Parkinson Study Group (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,844

Show all 68 references

Research works printed but not linked: 2

Mollenhauer, 2006, Proteome analysis of cerebrospinal fluid by mass spectrometry: a platform for marker development in synucleinopathies, Movement Disorders, 21
Schlossmacher, 2006, Monitoring of alpha-synuclein steady-state levels in vivo by ELISA, Movement disorders, 21

Sorted by citations

Items 301–382 of 382

Phosphorylated a-Synuclein in Parkinson's Disease
Wang, Y., Shi, M. Y., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, Y.-K., Siderowf, A. D., et al. (2016) · Cited by 7
Lasting Impact: Exploring the Brain Mechanisms that Link Traumatic Brain Injury to Parkinson’s Disease
Edwards, S., Corrigan, F., & Collins‐Praino, L. E. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04706-x · Cited by 8
A personalised and comprehensive approach is required to suppress or replenish SNCA for Parkinson’s disease
Li, D., Yau, W. Y., Chen, S., Wilton, S. D., & Mastaglia, F. L. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00887-3 · Cited by 7
The Use of Biomarkers for Prediction and Prevention of Alzheimer’s and Parkinson’s Diseases
Mandel, S. A., & Korczyn, A. D. (2012) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-5866-7_6 · Cited by 6
Neuroproteomics and Parkinson’s disease: don’t forget human samples
Licker, V., & Burkhard, P. R. (2011) · Expert Review of Proteomics · doi:10.1586/epr.11.29 · Cited by 6
An Update on CSF Biomarkers of Parkinson’s Disease
LeWitt, P. A., Huber, B. R., & Zhang, J. (2012) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-5866-7_8 · Cited by 6
Fluid biomarkers in atypical Parkinsonism: current state and future perspectives
Bougea, A. M., Colosimo, C., Falup‐Pecurariu, C., Palermo, G., & Değirmenci, Y. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02930-2 · Cited by 5
Key Connectomes and Synaptic‐Compartment‐Specific Risk Genes Drive Pathological α‐Synuclein Spreading
Li, Y., Torok, J., Zhang, S., Ding, J. L., Wang, N., Lau, C., Kulkarni, S., Anand, C., Tran, J., Cheng, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202413052 · Cited by 5
Microparticle immunocapture assay for quantitation of protein multimer amount and size
Gutknecht, M. F., Kaku, H., & Rothstein, T. L. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100214 · Cited by 5
The Quest for Anti-α-Synuclein Antibody Specificity—Lessons Learnt From Flow Cytometry Analysis
Leupold, L., Sigutova, V., Gerasimova, E. M., Regensburger, M., Zundler, S., Zunke, F., Xiang, W., Winner, B., & Prots, I. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.869103 · Cited by 5
Serum Autoantibodies as Biomarkers for Parkinsons Disease: Background and Utility
DeMarshall, C. A., Sarkar, A., & Nagele, R. G. (2015) · AIMS Medical Science · doi:10.3934/medsci.2015.4.316 · Cited by 5
Establishment of Method for the Determination of Aggregated α-Synuclein in DLB Patient Using RT-QuIC Assay
Park, S.-J., Lee, Y.-J., Park, J., Jin, H., Choi, M.-J., Jung, C., Akatsu, H., Choi, E.-K., & Kim, Y. (2020) · Protein and Peptide Letters · doi:10.2174/0929866527666200420105352 · Cited by 5
Parkinson‘s Disease: Diagnostic Relevance of Elevated Levels of Soluble α-Synuclein Oligomers In Cerebrospinal Fluid
Mukaetova‐Ladinska, E. B. (2011) · Future Neurology · doi:10.2217/fnl.11.7 · Cited by 5
Pedunculate oak forests (Quercus robur L.) survey in the Ticino Regional Park (Italy) by remote sensing
Rossini, M., Panigada, C., Meroni, M., Busetto, L., Castrovinci, R., & Colombo, R. (2007) · Forest - Rivista di Selvicoltura ed Ecologia Forestale · doi:10.3832/efor0450-0040194 · Cited by 5
Cerebrospinal fluid biomarkers in human prion diseases
Gawinecka, J., & Zerr, I. (2009) · Future Neurology · doi:10.2217/fnl.10.2 · Cited by 5
Hyaluronic Acid-Coated Solid Lipid Nanoparticles-Functionalized Quartz-Crystal Microbalance (QCM) Immunosensor for Label-Free Haptoglobin Detection: Toward Monitoring of Neuroinflammation
Lettieri, M., Talarico, L., Gabbricci, G., Clemente, I., Pepi, S., Landi, E., Fort, A., Vignoli, V., Tamasi, G., Magnani, A., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c05079 · Cited by 5
Molecular profiling in Parkinsonian syndromes: CSF biomarkers
Paoletti, F. P., Gaetani, L., & Parnetti, L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.002 · Cited by 5
Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination
Li, J., Mestre, T., Mollenhauer, B., Frasier, M. A., Tomlinson, J. J., Trenkwalder, C., Ramsay, T., Manuel, D. G., & Schlossmacher, M. G. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00360-5 · Cited by 4
Self-citation
„Big Data“ und künstliche Intelligenz zur Diagnoseunterstützung bei atypischer Demenz
Egger, K. E., & Rijntjes, M. (2018) · Der Nervenarzt · doi:10.1007/s00115-018-0568-3 · Cited by 4
Biomarkers of PD progression
Aarsland, D., & Ravina, B. M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f6f272 · Cited by 4
Non‐Dopaminergic Pathology of Parkinson's Disease
Braak, H., & Tredici, K. D. (2011) · Parkinson s Disease · doi:10.1002/9781444397970.ch3 · Cited by 4
Biomarkers for Lewy body diseases and other alpha-synucleinopathies in biofluids: current evidence and future directions
Russotto, A., Longobardi, A., Ciullini, A., Cazzaniga, F. A., Bacınoğlu, M. B., Borroni, B., Ghidoni, R., Moda, F., & Saraceno, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07471-6 · Cited by 5
Microfluidic platform for understanding Parkinson’s disease and α-synuclein conformation
Tregub, P. P., Zembatov, G. M., Namiot, E., Natalia, K., Stanislav, Y., Sergey, I., & Salmina, A. B. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00526-0 · Cited by 3
Subtype Specific CSF Biomarkers in Sporadic Creutzfeldt-Jakob Disease
Zafar, S., Younas, N., & Zerr, I. (2017) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000332 · Cited by 3
Dementia with Lewy bodies – a clinicopathological update
Bencze, J., Seo, W., Hye, A., Aarsland, D., & Hortobágyi, T. (2019) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-2613 · Cited by 4
Identifying Targets in α‐Synuclein Metabolism to Treat Parkinson Disease and Related Disorders
Tomlinson, J. J., Cullen, V., & Schlossmacher, M. G. (2010) · doi:10.1002/9780470572702.ch37 · Cited by 3
Self-citation
MS-Based Methods for Biomarkers of Parkinson’s Disease: What is The Future?
Barkovits, K., Helling, S., & Marcus, K. (2015) · Bioanalysis · doi:10.4155/bio.14.273 · Cited by 3
GaMOF@GaNPs hybrid nanostructure-enhanced SPR biosensor: Dual-target detection of Parkinson's disease biomarkers in serum
Wu, J., Wang, Y., Cao, J., Koh, K., & Chen, H. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.139363 · Cited by 2
Biomarkers of Parkinson’s disease
Jin, H., Kanthasamy, A., Anantharam, V., & Kanthasamy, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404630-6.00049-x · Cited by 2
Alzheimer’s Disease and Other Neurodegenerative Disorders
Rosén, C., Zetterberg, H., & Blennow, K. (2015) · Springer eBooks · doi:10.1007/978-3-319-01225-4_20 · Cited by 2
Cerebrospinal fluid biomarkers for neurodegenerative disorders
Videira, R. M. A. S. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer’s and Lewy Body Diseases
Schaeffer, M. J., Initiative, A. D. N., & Callahan, B. L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180962 · Cited by 2
Persistent Hyposmia as Surrogate for α-Synuclein-Linked Brain PathologyPreprint
Mollenhauer, B., Li, J., Schade, S., Weber, S., Trenkwalder, C., Concha‐Marambio, L., Tomlinson, J. J., aSCENT-PD Investigators, & Schlossmacher, M. G. (2023) · medRxiv · doi:10.1101/2023.12.19.23300164 · Cited by 2
Self-citation
Astrocytes and the Synucleinopathies
Koob, A. O., & Sacchetti, P. (2018) · Springer eBooks · doi:10.1007/978-981-13-0944-1_8 · Cited by 1
Cerebrospinal fluid sTREM2 mediates the associations of α-synuclein with tau pathology in older adults without dementia: two population-based study
Wang, Y.-C., Huang, L.-Y., Yan-Fu, Xiong, S.-Y., Wang, Z.-T., Tan, C., & Tan, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06729-3 · Cited by 1
Rapid Progression and Shorter Survival in Indians Affected with Probable MSA : A Prospective Cohort Study
Rukmani, M. R., Yadav, R., Bhaskarapillai, B., Pal, P. K., & Sathyaprabha, T. N. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70301 · Cited by 1
The Value of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Dementia
Bastard, N. L., & Engelborghs, S. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.11 · Cited by 1
Alpha-Synuclein as a Diagnostic Biomarker for Parkinson’s Disease
Bergström, J. J. E., & Ingelsson, M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_14 · Cited by 1
The role of molecular imaging in the frame of the revised dementia with Lewy body criteria
Sestini, S., Alongi, P., Berti, V., Calcagni, M. L., Cecchin, D., Chiaravalloti, A., Chincarini, A., Cistaro, A., Guerra, U. P., Pappatà, S., et al. (2019) · Clinical and Translational Imaging · doi:10.1007/s40336-019-00321-8 · Cited by 1
Parkinson’s Disease
Zhang, J., & Stewart, T. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00086-0 · Cited by 1
Biomarqueurs du liquide cérébrospinal dans la maladie à corps de Lewy
Bousiges, O. (2021) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(21)00192-1 · Cited by 2
Alpha-synuclein as a Molecular Marker for the Diagnosis of Neurological Disorders
Bagree, G., Silva, O. D., Liyanage, P. D., Mahasivam, S., Bansal, V., & Ramanathan, R. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837673216-00286 · Cited by 1
CFS Biomarkers in Parkinson’s Disease
Parnetti, L., Castrioto, A., De, C., Chiasserini, D., Tambasco, N., Rossi, A., Balducci, C., Beccari, T., & Calabresi, P. (2011) · InTech eBooks · doi:10.5772/16666 · Cited by 1
Prediction and targeted prevention of Parkinson's and Alzheimer's diseases
Mandel, S. A., Halperin, I. J. Y., Korczyn, A. D., & Morelli, M. (2009) · Cited by 1
Alpha-Synuclein: Biomarker for Parkinson’s Disease, It’s Estimation Methods, and Targeted Medicinal Therapies
Dhokne, S. V., Undale, V., Agrawal, D. C., & Pawar, S. D. (2021) · Springer eBooks · doi:10.1007/978-981-33-4141-8_9 · Cited by 1
Elevated phosphorylated α-synuclein and phosphorylated tau in Lrrk2 p.G2019S-mutant mice following influenza A pneumonitisPreprint
Lunn, M. O., Thakur, K., Lengacher, N. A., Hake-Volling, Q., aSCENT-PD Investigators, Tomlinson, J. J., Sad, S., Brown, E. G., & Schlossmacher, M. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.31.667659 · Cited by 1
Self-citation
Effects of Alpha-Synuclein on Cellular Homeostasis
Vekrellis, K., Minakaki, G., & Emmanouilidou, E. (2011) · InTech eBooks · doi:10.5772/17637
Identification of Novel Fluid Biomarkers for Alzheimer's Disease
Craig‐Schapiro, R. (2012) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7pr7t12
Detection of RNA in the Plasma of Patients with Sporadic Creutzfeldt–Jakob Disease, Gerstmann–Straüssler Syndrome and Other Non-Transmissible Spongiform Encephalopathy Brain Disorders
Tsukui, K., Iwasaki, Y., Nagaoka, M., & Tadokoro, K. (2010) · Microbiology Insights · doi:10.4137/mbi.s4043
Tesis doctoral UTILIDAD DE LA GAMMAGRAFÍA DE INERVACIÓN MIOCÁRDICA CON 123I-MIBG EN EL DIAGNÓSTICO CLÍNICO DE LA DEMENCIA DE CUERPOS DE LEWY
Camacho, V. (2014)
Les marqueurs biologiques de l'atrophie multisystématisée
Laurens, B. (2014) · HAL
The Role of Neutral Sphingolipids in the Pathogenesis of Parkinson Disease and Dementia with Lewy Bodies
Singh, P. (2013) · uO Research (University of Ottawa) · doi:10.20381/ruor-2936
Synucleinopathies
Alafuzoff, I. I., Pikkarainen, M., & Parkkinen, L. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107588660.009
Alpha-Synuclein in Cerebrospinal Fluid
Tokuda, T., Ishii, R., Tatebe, H., Kasai, T., & El‐Agnaf, O. M. A. (2016) · Springer eBooks · doi:10.1007/978-4-431-55948-1_13
Self-citation
Novel Biomarkers and the Diagnosis of Prion Diseases
Zafar, S. (2016) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.s8-011
Biomarkers in Cerebrospinal Fluid
Gawinecka, J., Schmitz, M., & Zerr, I. (2017) · Neuromethods · doi:10.1007/978-1-4939-7211-1_14
Modification of α-Synuclein by Phosphorylation: A Pivotal Event in the Cellular Pathogenesis of Parkinson’s Disease
Datta, I., & Ganapathy, K. (2017) · InTech eBooks · doi:10.5772/intechopen.70405
Neurochemical Aspects of Lewy Body Dementia
Farooqui, A. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816347-4.00004-0
a Circulating cell free mitochondrial DNA copy number variation in neurodegenerative disease
Lowes, H. (2018)
Insulin resistance and Parkinson’s disease
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819603-8.00007-9
Differentiating Alzheimer's disease from dementia with Lewy bodies
Bishnoi, R. J., Grossberg, G. T., & Manepalli, J. N. (2012) · Current psychiatry
The application of multimodal MRI in the identification of neurological biomarkers for Parkinson's disease and the investigation of the role of glymphatic system in the development of Parkinsonism
Cai, X. (2020) · Digital Repository Service (Northeastern University) · doi:10.17760/d20398331
Variant in the 3 0 region of SNCA associated with Parkinson's disease and serum a-synuclein levels
HuBeisha, Y., GuoXintian, T., Sun, W., & Zhang, L. S. Y. (2012)
CSF Biomarkers in Parkinson's disease
Parnetti, L., Castrioto, A., Carlo, C. D., Chiasserini, D., Tambasco, N., Rossi, A., Michiara, M., Beccari, T., & Calabresi, P. (2011)
Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors
Brás, I. C., & Outeiro, T. F. (2021) · International review of movement disorders · doi:10.1016/bs.irmvd.2021.08.002
Self-citation
Biomarkers of Parkinson's Disease
Jin, H., Kanthasamy, A., Anantharam, V., & Kanthasamy, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814655-2.00050-5 · Cited by 1
Dementia with Lewy Bodies
McKeith, I. G. (2010) · Springer eBooks · doi:10.1007/978-4-431-53871-4_18
Skin Biomarker in Parkinson Disease
Vincenzo, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-66513-4_8
Age-Dependent Effects of Paraquat-Induced Parkinsonism on Serum Alpha-Synuclein Expression, Substantia Nigra Histoarchitecture and Neurobehaviour in Male Wistar RatsPreprint
Ichie, K. E., Asomugha, L. A., & Okafor, I. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.20.689379
Additional file 4 of Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders
Li, J.-Q., Bi, Y.-L., Shen, X.-N., Wang, H.-F., Xu, W., Tan, C.-C., Dong, Q., Wang, Y.-J., Tan, L., & Yu, J.-T. (2020) · Figshare · doi:10.6084/m9.figshare.13279377
Additional file 1 of Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders
Li, J.-Q., Bi, Y.-L., Shen, X.-N., Wang, H.-F., Xu, W., Tan, C.-C., Dong, Q., Wang, Y.-J., Tan, L., & Yu, J.-T. (2020) · Figshare · doi:10.6084/m9.figshare.13279368
Additional file 5 of Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders
Li, J.-Q., Bi, Y.-L., Shen, X.-N., Wang, H.-F., Xu, W., Tan, C., Dong, Q., Wang, Y.-J., Tan, L., & Yu, J.-T. (2020) · Figshare · doi:10.6084/m9.figshare.13279380
Additional file 3 of Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders
Li, J.-Q., Bi, Y.-L., Shen, X.-N., Wang, H.-F., Xu, W., Tan, C., Dong, Q., Wang, Y.-J., Tan, L., & Yu, J.-T. (2020) · Figshare · doi:10.6084/m9.figshare.13279374
Additional file 2 of Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders
Li, J.-Q., Bi, Y.-L., Shen, X.-N., Wang, H.-F., Xu, W., Tan, C.-C., Dong, Q., Wang, Y.-J., Tan, L., & Yu, J.-T. (2020) · Figshare · doi:10.6084/m9.figshare.13279371
In situ NMR and integrative proteomics reveal the interaction signature of serum α-synuclein
Huang, J., Ahmed, R., Akimoto, M., Bozelli, J. C., Epand, R. M., & Melacini, G. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2521639123
Development of Inhibitors of Amyloid Fibril Propagation
Bendifallah, M. (2019) · theses.fr (ABES) · doi:10.70675/a872e5bdzc153z41f4z9472z725fd78aab48
Effets des mutations sur la structure et la dimérisation de l'alpha-synucléine et implications pour la maladie de Parkinson : réponses apportées par la dynamique moléculaire à gros grains
Guzzo, A. (2022) · theses.fr (ABES) · doi:10.70675/0849285az2731z415cza277z0e56728f62bc · Cited by 1
Body Fluid-based Biomarkers for Cognitive Impairment in Parkinson’s Disease
Ragini, R., Choudhury, S., Krithika, N. C., Bharath, M. M. S., Rathod, B. L. S., Yadav, R., & Alladi, P. A. (2026) · Annals of Neurosciences · doi:10.1177/09727531261442666
Age-related susceptibility to paraquat-induced neurotoxicity in male wistar rats: effects on neurobehaviour, substantia nigra cytoarchitecture, and alpha-synuclein levels
Ichie, K. E., Asomugha, A. L., & Okafor, I. A. (2026) · BMC Neuroscience · doi:10.1186/s12868-026-01019-0
Spreading α-synuclein rewires organelle communication and impairs neuron–astrocyte mitochondrial quality controlPreprint
Fritsch, E., Horvatović, K., Otte, P. S., Koudelka, T., Rossius, J., Braeuning, C., Breimann, L., Piazza, I., & Birol, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.19.733342
Amyloid, p‐tau, neurofilament light, and α‐synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease
Rizzo, M., Teunissen, C. E., Zetterberg, H., Blennow, K., Kollmorgen, G., Krüger, R., Fernandes, S. B. G., Aarsland, D., Borejko, O., Hu, O. M., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70498
Predicting cognitive impairment in Parkinson's disease using neurophysiology and biochemical parameters as biomarkers
Yarnall, A. J. (2013)

Authors: Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., Trenkwalder, C., Sarracino, D. A., VonSattel, J.-P., Locascio, J. J., El-Agnaf, O. M. A., & Schlossmacher, M. G.
Affiliations: Brigham and Women's Hospital (US)
Harvard University (US)
University of Ottawa (CA)
Ludwig-Maximilians-Universität München (DE)
Paracelsus Elena Klinik Kassel (DE)
Columbia University (US)
Corresponding author: Schlossmacher, Michael G.
ORCID: Mollenhauer, Brit
Kahn, Ilana
Outeiro, Tiago F.
McLean, Pamela J.
Trenkwalder, Claudia
Locascio, Joseph J.
Schlossmacher, Michael G.
Venue: Experimental Neurology
Publisher: Elsevier BV
Published: 2008-10
Volume: 213
Issue: 2
Pages: 315-325
ISSN: 0014-4886 (ISSN-L)
DOI: 10.1016/j.expneurol.2008.06.004
OpenAlex: W2003260773
Cited by: 382
References: 68
Citations by year: 2026: 6 · 2025: 18 · 2024: 8 · 2023: 9 · 2022: 22 · 2021: 16 · 2020: 25 · 2019: 19 · 2018: 16 · 2017: 17 · 2016: 20 · 2015: 25 · 2014: 32 · 2013: 26 · 2012: 30
FWCI: 19.25
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Experimental Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Neurological Disorders and Stroke (P50NS038375, 5P50-NS038375)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: alpha-synuclein, cerebrospinal fluid, Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease, Creutzfeldt-Jakob disease, synucleinopathies, cell-free biomarkers, ELISA quantification, neurodegeneration, prion disease, cell death
MeSH terms: Adult, Aged, Aged, 80 and over, Amino Acid Sequence, Animals, Cells, Cultured, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Molecular Sequence Data, Nerve Degeneration, Biomarkers, Mice, Rats, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks